Biotech’s real estate market is still upside down

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top CMS official.

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. 

Good morning. It’s another busy news day, and I’m layering up at home to avoid turning the heater on. Fall is officially here.

Read the rest…